North American Prodromal Synucleinopathy Consortium

This study will enroll participants with idiopathic rapid eye movement (REM) sleep behavior disorder (RBD), for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Washington University School of Medicine

Collaborator: Mayo Clinic

Stanford Investigator(s):


Inclusion Criteria:

   - Idiopathic REM sleep behavior disorder

Exclusion Criteria:

   - REM sleep behavior disorder secondary to another cause (ex: narcolepsy, dementia,
   Parkinson's Disease, etc)

   - Other neurological disorder

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305